baltimore conference logo
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Survival Differences in KRAS/BRAF Mutations in mCRC

July 10, 2015
Halfdan Sorbye, MD

Special Reports, Gastrointestinal Cancers (Issue 5), Volume 4, Issue 2

Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).